Tenax Therapeutics to Present at Upcoming Investor Conferences
September 20 2018 - 8:30AM
Business Wire
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty
pharmaceutical company focused on identifying, developing and
commercializing products for the critical care market, today
announced that company management will present at the following
upcoming investor conferences:
Event: The MicroCap ConferencePresenter: Anthony
DiTonno, CEODate: October 1, 2018Time: 9:30 AM
ETLocation: JW Marriott Essex House, New York, NY
Event: Ladenburg Thalmann 2018 Healthcare
ConferencePresenter: Anthony DiTonno, CEODate:
October 2, 2018Time: 9:00 AM ETLocation: Sofitel New
York Hotel, New York, NY
For more information, please visit the company website at
www.tenaxthera.com.
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company
focused on identifying, developing and commercializing products for
the critical care market. The Company has a world-class scientific
team including recognized global experts in pulmonary hypertension.
The Company owns the North American rights to develop and
commercialize levosimendan and is finalizing preparations to begin
their Phase 2 clinical trial for the use of levosimendan in the
treatment of Pulmonary Hypertension associated with Heart Failure
and preserved Ejection Fraction (PH-HFpEF) in the fourth quarter of
2018. For more information, visit www.tenaxthera.com.
About Levosimendan
Levosimendan is a calcium sensitizer that works through a unique
triple mechanism of action. It initially was developed for
intravenous use in hospitalized patients with acutely decompensated
heart failure. It was discovered and developed by Orion Pharma,
Orion Corporation of Espoo Finland, and is currently approved in
over 60 countries for this indication and not available in the
United States. Tenax Therapeutics acquired the North American
rights to develop and commercialize levosimendan from Phyxius
Pharma, Inc.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by
the Company that involve risks and uncertainties and reflect the
Company’s judgment as of the date of this release. The
forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to matters beyond the
Company’s control that could lead to delays in the clinical study,
new product introductions and customer acceptance of these new
products; matters beyond the Company’s control that could impact
the Company’s continued compliance with Nasdaq listing
requirements; the impact of management changes on the Company’s
business and unanticipated charges, costs and expenditures not
currently contemplated that may occur as a result of management
changes; and other risks and uncertainties as described in the
Company’s filings with the Securities and Exchange Commission,
including in its annual report on Form 10-K filed on April 2, 2018,
its quarterly report on Form 10-Q filed on August 14, 2018 as well
as its other filings with the SEC. The Company disclaims any intent
or obligation to update these forward-looking statements beyond the
date of this release. Statements in this press release regarding
management’s future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180920005105/en/
Investor Contact:ICRStephanie Carrington,
646-277-1282Stephanie.carrington@icrinc.com
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Sep 2023 to Sep 2024